Treatment of Lambert-Eaton Myasthenic Syndrome in Associated Malignancy
Clinical Scenario
This protocol addresses Lambert-Eaton myasthenic syndrome (LEMS) occurring in the context of an associated malignancy — a paraneoplastic presentation that requires a targeted clinical approach distinct from idiopathic LEMS.
Condition Context
Paraneoplastic LEMS
LEMS can occur as a paraneoplastic disease (pLEMS) in association with malignancy — most notably in long-time smokers, particularly in the context of small-cell lung cancer (SCLC). This paraneoplastic form differs epidemiologically and clinically from idiopathic LEMS (iLEMS), which predominantly affects women under 50 years of age.
Treatment Approach Partial — full regimen in protocol
When crisis-like deterioration occurs in this setting, rapid immunomodulatory intervention is indicated. Intravenous immunoglobulin therapy is among the established options considered — the complete algorithm, full list of alternatives, and clinical decision points are available in the structured protocol.
References
- LEMS can be idiopathic (iLEMS; mostly women younger than 50 years) or, less commonly – especially in small-cell lung cancer (SCLC) – as a paraneoplastic disease (pLEMS; mostly in long-time smokers).
- IVIg or, if appropriate, PE/IA must be used to treat the crisis worsening.
DOI: 10.1177/17562864231213240
View source ↗